BeckRW, RiddlesworthT, RuedyK, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317:371–378.
2.
BekiariE, KitsiosK, ThabitH, et al.: Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ, 2018; 361:k1310.
3.
CryerPE: Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med, 2013; 369:362–372.
4.
El-KhatibFH, BalliroC, HillardMA, et al.: Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet, 2017; 389:369–380.
5.
RussellSJ, El-KhatibFH, SinhaM, et al.: Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med, 2014; 371:313–325.
6.
RussellSJ, HillardMA, BalliroC, et al.: Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol, 2016; 4:233–243.
7.
CastleJR, El YoussefJ, WilsonLM, et al.: Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care, 2018; 41:1471–1477.
8.
TalebN, HaidarA, MessierV, et al.: Glucagon in artificial pancreas systems: potential benefits and safety profile of future chronic use. Diabetes Obes Metab, 2017; 19:13–23.
HovelmannU, BystedBV, MouritzenU, et al.: Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care, 2018; 41:531–537.
11.
AuthierF, DesbuquoisB: Glucagon receptors. Cell Mol Life Sci, 2008; 65:1880–99.
12.
ChatilaR, WestAB: Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine, 1996; 75:327–33.
